WALTHAM, Mass., Oct. 5, 2026 – Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunologic, metabolic, and rare diseases, today announced that Fierce Biotech has named it to its “Fierce 15” list of the most innovative and promising private biotechnology companies of 2026. Every year, the leading industry news outlet evaluates hundreds of early-stage companies from around the world and recognizes a select number based the strength of their technology, partnerships, venture backers, competitive market position, and other factors. Sironax was specifically recognized for “taking aim at some bold targets.”
“As we advance our clinical-stage programs toward Phase 2 and develop a number of promising early-stage candidates, this has been a year of remarkable achievement for our company thanks to the commitment of our entire global team,” said Dr. Shefali Agarwal, Sironax President and CEO. “We are honored Fierce Biotech has named us to a distinguished list of emerging biotechs based on our scientific innovation and growth potential. Such recognition serves to further inspire us to continue developing transformative therapies for critical unmet medical conditions.”
Sironax’s clinical-stage pipeline consists of first- or potentially best-in-class molecules. The company is developing SIR2501, a first-in-class allosteric inhibitor of SARM1, to prevent neuroaxonal damage in diseases such as ALS and chemotherapy-induced peripheral neuropathy (for which it was granted Fast Track designation by the FDA). Sironax is also developing SIR4156, an allosteric and globally first-in-class NAMPT activator for metabolic dysfunction, and SIR9900, a highly selective, brain-penetrant allosteric RIPK1 inhibitor as a potential treatment for inflammatory and immunological diseases. In addition, Sironax has rights to develop selected assets using its recently acquired brain delivery platform and is also developing new platforms to further address the blood-brain barrier challenge.
“For 24 years, the Fierce 15 has highlighted private biotechs doing some of the most interesting and ambitious work in the industry,” said Ayla Ellison, Editor-in-Chief, Fierce Life Sciences and Healthcare. ”This year’s class arrives at a moment when momentum is returning to biotech, with more capital flowing and new opportunities opening up for promising companies. These 15 biotechs stand out for the strength of their science and the potential of their approaches to shape the next generation of medicines.”
关于维泰瑞隆
维泰瑞隆是一家临床阶段的生物科技公司，致力于开发神经退行性疾病、炎症免疫性疾病、代谢性疾病以及罕见病的变革性疗法。自2017年成立以来，维泰瑞隆已构建起一个多元化项目研发管线，聚焦衰老、退行性病变、代谢功能障碍和炎症的关键致病机理。维泰瑞隆正在开展多个项目的临床研究，包括SARM1抑制剂SIR2501、NAMPT激动剂SIR4156和RIPK1抑制剂SIR9900，同时持续推进临床前研究。公司入选2025年度Endpoints 11最具潜力生物技术初创公司榜单。如需了解更多信息，请访问sironax.com。